Pension Fund Group v. Tempur-Pedic International, Inc.

614 F. App'x 237
CourtCourt of Appeals for the Sixth Circuit
DecidedJune 4, 2015
Docket14-5696
StatusUnpublished
Cited by10 cases

This text of 614 F. App'x 237 (Pension Fund Group v. Tempur-Pedic International, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pension Fund Group v. Tempur-Pedic International, Inc., 614 F. App'x 237 (6th Cir. 2015).

Opinion

COOK, Circuit Judge.

After posting record sales for five straight quarters, mattress manufacturer Tempur-Pedic International, Inc.’s business declined in the second quarter of 2012. Plaintiffs-Appellants — a group of pension funds who purchased Tempur-Pedic stock before the price-per-share fell nearly seventy-five percent over a seven-week period — filed a consolidated class-action complaint against Defendants-Ap-pellees Tempur-Pedic, president and chief executive officer Mark A. Sarvary, and executive vice president and chief financial officer Dale E. Williams (collectively, “Tempur-Pedic”) on behalf of all investors who purchased Tempur-Pedic common stock between January 25, 2012, and June 5, 2012 (“the Class Period”). The complaint alleges that Tempur-Pedic misled investors by issuing rosy financial projections and failing to disclose the company’s deteriorating competitive position.

The district court dismissed the complaint for failure to state a plausible claim of securities fraud. We AFFIRM.

I.

Tempur-Pedic manufactures and distributes viscoelastic (i.e., memory-foam) mattresses and pillows. Its primary competitors — Sealy, Serta, and Simmons — historically sold innerspring mattresses, which accounted for the bulk of mattresses sold in the United States. Tempur-Pedic, in contrast, targets the “specialty premium” market for non-inner-spring mattresses that retail for at least $1,000.

In April 2011, Serta launched its competing “iComfort” gel-foam mattress line. According to the complaint, several iCom-fort mattresses cost less than Tempur-Pedic’s cheapest model, and Serta’s advertising touted the gel-based iComfort’s technological superiority over traditional memory-foam mattresses. The pension funds contend that Tempur-Pedic’s management grew concerned about Serta’s inroads in the memory-foam market even though Tempur-Pedic’s sales continued to grow in the aggregate throughout 2011. According to a former Tempur-Pedic business development manager, sales at his retail accounts declined forty to sixty percent within a three-month period after retailers began selling the iComfort. He provided the pension funds with company emails soliciting weekly sales reports and a *241 document titled “iComfort Risk Analysis for Mark Meeting Sept 11” that compared Tempur-Pedic’s sales at certain retailers before and after Serta introduced the iComfort. According to the pension funds, the “Risk Analysis” document shows that Tempur-Pedic’s year-over-year sales grew by three percent between April and September 2011 at retailers that carried the iComfort and thirty-three percent at comparable mid-size retailers that did not. The former business development manager also disclosed that company executives learned at an August 2011 industry conference that four of the company’s highest-grossing accounts planned to start carrying the iComfort in January 2012.

Notwithstanding Serta’s inroads, Tem-pur-Pedic reported a company-record $1.4 billion in net sales in 2011 — a twenty-eight percent increase over 2010. On January 24, 2012, Tempur-Pedic released financial guidance projecting that its annual net sales would grow by about fifteen percent in 2012 and total between $1.6 and $1.65 billion for the year. By mid-April, the company appeared to be on track to meet or exceed its projections: net sales for the first quarter of 2012 surpassed the previous year’s first-quarter sales by eighteen percent. But business slowed soon thereafter. On June 6, the company revised its full-year guidance downward to $1.43 billion in projected net sales, explaining in a press release that “[sjales trends in our North America business during the second quarter have been disappointing and below plan, primarily due to changes in the competitive environment, including an unprecedented number of new competitive product introductions, which have been supported by aggressive marketing and promotion.” (R. 91-31, June 6, 2012 Form 8-K.)

Tempur-Pedic’s stock price hit a Class Period high of $87.26 per share on April 19, 2012, before declining precipitously over the next month-and-a-half. The stock price dropped to $66.53 on April 20 after the company adhered to its full-year guidance despite its better-than-predicted first quarter. It fell again to $48:29 per share in early May after Tempur-Pedic issued a press release announcing a Memorial Day discount on its Cloud Supreme mattress line. Finally, after the company revised its yearly projections downward on June 6, the stock price hit a Class Period low of $22.39 per share.

Ultimately, Tempur-Pedic’s 2012 net sales totaled $1.4 billion. According to the pension funds, those results confirm that the initial projection ($1.6 to $1.65 billion) was “wildly off the mark and ... had no reasonable basis in fact.” They maintain that Tempur-Pedic, Sarvary, and Williams violated Section 10(b) of the Securities Exchange Act of 1934,15 U.S.C. § 78j(b), and related Securities and Exchange Commission (SEC) Rule 10b-5, 17 C.F.R. § 240.10b-5, by touting the company’s recent successes and issuing rosy financial projections while failing to disclose that sales growth slowed at retailers carrying Serta’s iComfort.

Tempur-Pedic, Sarvary, and Williams moved to dismiss the pension funds’ consolidated amended complaint for failure to state a plausible securities-fraud claim. The pension funds opposed that motion and sought leave to file a second amended complaint that included two exhibits referenced in the first amended complaint. The district court granted the motion to dismiss and denied the motion to amend, finding that none of the challenged statements were actionable and that amendment would be futile. The pension funds timely appealed.

II.

We review the district court’s decision to dismiss the complaint de novo, “con- *242 stru[ing] the complaint in the light most favorable to the plaintiff’ and “accepting] all well-pleaded factual allegations as true.” La. Sch. Emps. Ret. Sys. v. Ernst & Young, LLP, 622 F.3d 471, 477 (6th Cir.2010).

“To state a securities fraud claim ..., a plaintiff must allege, in connection with the purchase or sale of securities, the misstatement or omission of a material fact, made with scienter, upon which the plaintiff justifiably relied and which proximately caused the plaintiffs injury.” Frank v. Dana Corp., 547 F.3d 564, 569 (6th Cir.2008) (internal quotation marks and citation omitted). A defendant is liable for omitting a fact only if he had a duty to disclose it. City of Monroe Emps. Ret. Sys. v. Bridgestone Corp., 399 F.3d 651, 669 (6th Cir.2005). But a defendant who speaks voluntarily on a subject when he has no duty to do so ‘assume[s] a duty to speak fully and truthfully on th[at] subject.’” Helwig v. Vencor, Inc., 251 F.3d 540

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
614 F. App'x 237, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pension-fund-group-v-tempur-pedic-international-inc-ca6-2015.